ATE509104T1 - Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie - Google Patents

Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie

Info

Publication number
ATE509104T1
ATE509104T1 AT09150109T AT09150109T ATE509104T1 AT E509104 T1 ATE509104 T1 AT E509104T1 AT 09150109 T AT09150109 T AT 09150109T AT 09150109 T AT09150109 T AT 09150109T AT E509104 T1 ATE509104 T1 AT E509104T1
Authority
AT
Austria
Prior art keywords
dna
gene therapy
encapsuled
vaccination
microparticle
Prior art date
Application number
AT09150109T
Other languages
English (en)
Inventor
Graham Henry Farrar
David Hugh Jones
James Christopher Stephen Clegg
Original Assignee
Health Prot Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Health Prot Agency filed Critical Health Prot Agency
Application granted granted Critical
Publication of ATE509104T1 publication Critical patent/ATE509104T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/12011—Reoviridae
    • C12N2720/12311—Rotavirus, e.g. rotavirus A
    • C12N2720/12334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Manufacturing & Machinery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AT09150109T 1997-05-15 1998-05-15 Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie ATE509104T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9709900.6A GB9709900D0 (en) 1997-05-15 1997-05-15 Microencapsulated DNA for vaccination and gene therapy

Publications (1)

Publication Number Publication Date
ATE509104T1 true ATE509104T1 (de) 2011-05-15

Family

ID=10812381

Family Applications (2)

Application Number Title Priority Date Filing Date
AT98921621T ATE420194T1 (de) 1997-05-15 1998-05-15 Verfahren zur herstellung von mikroverkapselten dns zur impfung und zur gentherapie
AT09150109T ATE509104T1 (de) 1997-05-15 1998-05-15 Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT98921621T ATE420194T1 (de) 1997-05-15 1998-05-15 Verfahren zur herstellung von mikroverkapselten dns zur impfung und zur gentherapie

Country Status (8)

Country Link
EP (2) EP0971693B1 (de)
JP (2) JP4827273B2 (de)
AT (2) ATE420194T1 (de)
AU (1) AU735897B2 (de)
CA (1) CA2289761C (de)
DE (1) DE69840434D1 (de)
GB (1) GB9709900D0 (de)
WO (1) WO1998051279A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197229B1 (en) * 1997-12-12 2001-03-06 Massachusetts Institute Of Technology Method for high supercoiled DNA content microspheres
GB9810236D0 (en) * 1998-05-13 1998-07-08 Microbiological Res Authority Improvements relating to encapsulation of bioactive agents
CA2276066A1 (en) * 1999-03-11 2000-09-11 Zycos Inc. Microparticles for delivery of nucleic acid
JP5224313B2 (ja) * 2007-02-27 2013-07-03 公立大学法人横浜市立大学 プラスミド送達用粒子
JP5248199B2 (ja) * 2008-05-26 2013-07-31 株式会社ティラド 凝縮器
US9814657B2 (en) 2009-04-27 2017-11-14 Premier Dental Products Company Buffered microencapsulated compositions and methods
US10688026B2 (en) 2009-04-27 2020-06-23 Premier Dental Products Company Buffered microencapsulated compositions and methods

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686098A (en) 1984-05-14 1987-08-11 Merck & Co., Inc. Encapsulated mouse cells transformed with avian retrovirus-bovine growth hormone DNA, and a method of administering BGH in vivo
JPH0720859B2 (ja) * 1985-02-07 1995-03-08 武田薬品工業株式会社 マイクロカプセルの製造法
EP0248531A3 (de) 1986-05-02 1988-09-28 Southern Research Institute Verkapselte Nukleinsäuren
DK0471036T4 (da) 1989-05-04 2004-07-19 Southern Res Inst Indkapslingsfremgangsmåde
AU629316B2 (en) 1990-04-11 1992-10-01 Flora Inc. Periodontal disease treatment system
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
CA2160878A1 (en) 1993-04-19 1994-10-27 Medisorb Technologies International L.P. Encapsulation of nucleic acids with conjugates that facilitate and target cellular uptake and gene expression
EP0714308A4 (de) 1993-08-26 1998-07-29 Univ California Methode, zusammensetzungen und vorrichtungen zur verabreichung von nackten polynukleotiden, welche für biologisch aktive peptide kodieren
DE69431404T2 (de) * 1993-10-22 2003-04-30 Genentech Inc., San Francisco Verfahren zur mikroverkapselung von antigenen und verwendung der zusammensetzungen als impfstoffe
ATE223702T1 (de) * 1993-10-22 2002-09-15 Genentech Inc Verfahren und zusammensetzungen zur mikrokapselung von adjuvantien
ATE475668T1 (de) * 1994-01-27 2010-08-15 Univ Massachusetts Medical Immunisierung durch impfung von dns transkriptionseinheit
EP0804249A2 (de) * 1994-03-15 1997-11-05 Brown University Research Foundation Polymeres system zur freisetzung von genen
US5571531A (en) 1994-05-18 1996-11-05 Mcmaster University Microparticle delivery system with a functionalized silicone bonded to the matrix
AUPM572294A0 (en) 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
DE69608122T3 (de) * 1995-11-09 2011-06-16 Microbiological Research Authority Camr, Salisbury Mikroverkapselte dna zur impfung und gentherapie

Also Published As

Publication number Publication date
WO1998051279A3 (en) 1999-02-18
ATE420194T1 (de) 2009-01-15
JP2002508751A (ja) 2002-03-19
GB9709900D0 (en) 1997-07-09
JP4827273B2 (ja) 2011-11-30
EP0971693A2 (de) 2000-01-19
EP0971693B1 (de) 2009-01-07
DE69840434D1 (de) 2009-02-26
CA2289761C (en) 2008-08-26
AU735897B2 (en) 2001-07-19
EP2042599A1 (de) 2009-04-01
CA2289761A1 (en) 1998-11-19
JP2011105774A (ja) 2011-06-02
EP2042599B1 (de) 2011-05-11
AU7440898A (en) 1998-12-08
WO1998051279A2 (en) 1998-11-19

Similar Documents

Publication Publication Date Title
DE3773633D1 (de) Verfahren zur direkten herstellung von kaugummigrundmasse fuer kaugummimasse und kaugummi.
DE68928934D1 (de) Verfahren zur herstellung von menschlicher dnase
ATE252640T1 (de) Verbindungen zur immunotherapie und diagnose von tuberkulose
ATE315088T1 (de) Tumorassoziierte antigenderivate der mage-familie,nukleinsäuresequenzen die dafür kodieren, zur herstellung von fusionsproteinen und zusammensetzungen zur impfung
DE69618601D1 (de) Herstellung von einer immunantwort gegen prostat-spezifisches antigen (psa)
DE69435331D1 (de) Herstellung von menschlichen papillomavirus HBV-11 Kapsidprotein L1 und Virus-ähnliche Partikeln
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
DE69203229D1 (de) Verfahren zur herstellung von wiederaufladbarem abgeändertem mangandioxid-material und ähnliche verbindungen sowie elektrodenmaterial.
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
DE3750176D1 (de) Impfstoff und verfahren zur herstellung.
DE3575520D1 (de) Rabies-vakzine und verfahren zur herstellung.
ATE195346T1 (de) Rekombinante dna moleküle die aminopeptidase enzyme kodieren und ihre anwendung für die herstellung von impfstoffen gegen helminth infektionen
DE69326559D1 (de) Rekombinante methode und wirt zur herstellung von xylitol
ATE509104T1 (de) Verfahren zur herstellung von mikroverkapselter dna zur impfung und gentherapie
ATE192334T1 (de) Mikroverkapselte dna zur impfung und gentherapie
DE3870775D1 (de) Verfahren zur herstellung von kieselsaeuregelteilchen.
DE60140950D1 (de) Neuer gentherapeutischer wirkstoff zur behandlung g
DE3885752D1 (de) Methode und verbindungen zur herstellung von acsf und acsf-antagonisten.
ATE132160T1 (de) Verfahren zur reinigung von aussenmembran-protein von haemophilus influenza
DE3766046D1 (de) Verfahren zur herstellung von isopropylakohol und tertiaeren c4-bis c5-alkoholen.
DE59508988D1 (de) Vakzine zur Immunisierung gegen TBE-Virusinfektionen sowie ein Verfahren zu dessen Herstellung
DE3671603D1 (de) Verfahren zur zucht von babesia canis, verwendung zur herstellung von antigenen und impfstoffen und antigene und impfstoffe gegen piroplasmose.
DE69403197D1 (de) Die verwendung von anti-helminth impfstoffen zur kontrolle von parasitären krankheiten, die mit einem verlust der natürlichen immunität assoziiert sind
CA2236925A1 (en) Microencapsulated dna for vaccination and gene therapy
ATE65543T1 (de) Dna-sequenzen des ebv-genoms, rekombinante dnamolek¨le, verfahren zur herstellung von ebvverwandten antigenen sowie diagnostische zusammensetzungen und pharmazeutische zusammensetzungen, die die genannten antigene enthalten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties